Literature DB >> 8003550

Determination of remifentanil in human and dog blood by HPLC with UV detection.

K Selinger1, C Lanzo, A Sekut.   

Abstract

Remifentanil (GI87084) is a phenylaminopiperidine derivative of the fentanyl type with a potent analgesic activity and ultra-short half-life. The N-substituted labile methyl propanoate ester group is highly susceptible to cleavage by endogenous esterases and by chemical hydrolysis. The hydrolysis is stopped by addition of 20 microliters of 50% citric acid per 1 ml of blood. The method involves a liquid extraction of chilled blood at pH 7.4 with butyl chloride and back-extraction into 0.01 M HCl. The chromatographic conditions are: column--Zorbax SB-CN 4.6 x 250 mm; mobile phase--7% acetonitrile--14% methanol in phosphate buffer (0.03 M; pH 3.0); detection--UV at 210 nm. The internal standard used was GI97559--an ethyl analogue of the drug. The method has been validated in human blood over the range of 1-200 ng ml-1 and in dog over the range 10-60, 135 ng ml-1 with the latter assay being used in a toxicological support study. Additionally, it was used to characterize the hydrolysis of the drug, the enzymes involved in the process, and ex vivo drug interactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8003550     DOI: 10.1016/0731-7085(94)90035-3

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

Review 1.  The clinical pharmacology of remifentanil: a brief review.

Authors:  Talmage D Egan
Journal:  J Anesth       Date:  1998-12       Impact factor: 2.078

2.  Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia.

Authors:  Jörn Lötsch; Carsten Skarke; Jutta Darimont; Michael Zimmermann; Lutz Bräutigam; Gerd Geisslinger; Alfred Ultsch; Bruno G Oertel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-18       Impact factor: 3.000

Review 3.  Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal.

Authors:  T D Egan
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

4.  Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix.

Authors:  Raymond N Xu; Jill Polzin; Michelle Kranz; Phillip Vaca; Maria Metchkarova; Matthew J Rieser; Tawakol A El-Shourbagy
Journal:  Pharmaceutics       Date:  2010-04-30       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.